Q3 2024 Earnings Call Transcript November 14, 2024 Emily Bodnar – H.C. Wainwright: Operator: Thank you for standing by. I ...

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer BenefitPRAME-TCR iNKT Overcomes Challenges from ...

CiRA researchers found that reprogramming one type of iNKT cells to iPS cells and then differentiating them back results in reprogrammed iNKT cells (re-iNKT cells) that show properties of another ...

The frequency and activity of convential T cells serves as an early childhood immune signature that predicts the development of asthma later on. iNKT cells are shown in green, lung vasculature in ...

Mink Therapeutics, Inc. ( (INKT) ) has released its Q3 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to ...

The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR. AgenT-797 Combination Boosts Activity of Checkpoint Inhibitors and Bispecific Engagers in ...

PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage ...

The presentations showcased new data from MiNK’s iNKT cell therapy programs, agenT-797 and PRAME-TCR. “The data we presented at SITC reflect the potential of iNKT cell therapies to offer ...

PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage ...